|Bid||0.000 x 100|
|Ask||1.380 x 1000|
|Day's Range||0.8950 - 1.0300|
|52 Week Range||0.8900 - 5.7500|
|Beta (3Y Monthly)||3.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 28, 2018 - Dec 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen (BIIB.O) from future royalty payments to Forward. Biogen did not immediately respond to a request for comment. The companies had been locked in a dispute over patents for dimethyl fumarate, the key active ingredient in Tecfidera, the leading oral MS treatment.
A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S. The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen from future royalty payments to Forward. Biogen did not immediately respond to a request for comment.
Forward Pharma A/S (FWP) (“Forward” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) has affirmed the decision of the Patent Trial and Appeal Board (the “PTAB”) in the interference proceeding (the “Interference”) between Forward’s U.S. Patent Application No. 11/576,871 (the “’871 application”) and an issued Biogen patent. “We are disappointed with the Federal Circuit’s decision to affirm the decision of the PTAB. As we have indicated throughout the appeal process, under the Settlement and License Agreement with Biogen, a positive outcome from the Interference after exhaustion of all appeals is among the conditions that must be satisfied for future royalties from the net sales of Tecfidera® in the United States to be payable to Forward,” said Dr. Claus Bo Svendsen, Chief Executive Officer of Forward.
Forward Pharma A/S (FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY. Dr. Svendsen will present a corporate update on Tuesday, October 2, 2018 at 11:30AM ET and will be available for one-on-one meetings. Investors and other interested parties may access a live audio webcast of Dr. Svendsen’s conference presentation by visiting the investor page on the Company’s website (ir.forward-pharma.com).
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...
COPENHAGEN, Denmark, Sept. 19, 2018-- Forward Pharma A/S, today reported consolidated financial results for the six-month period ended June 30, 2018. Net loss for the six-month period ended June 30, 2018 ...
NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial ...